Myocardial perfusion stress test: is it worth?

Area of Science:

• Cardiology
• Nuclear Medicine
• Diagnostic Imaging

Background:

• Dyslipidemic patients with intermediate pre-test probability for ischemic heart disease require accurate diagnostic tools.
• Comparing the diagnostic utility of Technetium Tc 99m-sestamibi myocardial perfusion stress test (MPS) and stress echocardiography (SEHO) is crucial.

Purpose of the Study:

• To evaluate the utility of MPS compared to SEHO in dyslipidemic patients with intermediate pre-test probability for ischemic heart disease.
• To assess the predictive value of MPS and SEHO for new-onset cardiac events.

Main Methods:

• 56 dyslipidemic patients with suspected/known ischemic heart disease underwent both MPS and SEHO.
• Patients were followed for a mean of 25.77 months for cardiac events and coronary angiography (CA).
• Statistical analysis, including correlation and ROC curve analysis, was performed.

Main Results:

• MPS was positive in 80% of patients, SEHO in 68%.
• Both tests correlated well with CA findings.
• Cardiac events occurred in 57% of patients; MPS results (SSS, SDS) significantly predicted events (p < 0.05).
• MPS sensitivity was 91%, specificity 56%; SEHO sensitivity 85%, specificity 61%.

Conclusions:

• MPS is a valuable tool for predicting future cardiovascular events in dyslipidemic patients with intermediate pre-test probability.
• Quantifiable data from MPS, coupled with reduced radiation doses, may position it as a preferred diagnostic method.